A Case of Type 2 Diabetes Mellitus with NASH Successfully Treated Using Integrated Therapy Including Ipragliflozin

Abstract

Ipragliflozin is a novel selective inhibitor of sodium glucose co-transporter 2 (SGLT2 inhibitor) in clinical development for the treatment of type 2 diabetes mellitus. SGLT2 inhibitors improve glycemic control by not enhancing insulin secretion, with the additional benefits of reductions in body weight, blood pressure and visceral fat as well as improvements in lipid metabolism. Therefore, effects in improving fat storage pathologies, such as fatty liver, are expected. We herein report the case of a patient who demonstrated improvements in glycemic control in addition to abnormalities in liver aminotransferases caused by non-alcoholic steatohepatitis (NASH) following reductions in body weight achieved under treatment with ipragliflozin and integrated therapy consisting of diet and exercise.